Rodman & Renshaw initiated coverage of BioAtla (BCAB) with a Buy rating and $4 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB:
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/25
- BioAtla Creates Super-Voting Share to Advance Reverse Split
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/12/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/9/25
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/8/25